TauRx Pharmaceuticals

TauRx Pharmaceuticals is a clinical-stage biotechnology company dedicated to the development of innovative therapies and diagnostics for neurodegenerative diseases, specifically those characterized by tau protein aggregation, such as Alzheimer's disease and frontotemporal dementia (FTD). The company's research is built on the foundational science of tau aggregation inhibition, positioning it as a distinct alternative to the dominant amyloid-beta hypothesis in Alzheimer's research. Headquartered in Singapore with significant research operations in Aberdeen, Scotland, TauRx has remained a privately held entity. Its lead compound, hydromethylthionine mesylate (HMTM), is an oral small-molecule tau aggregation inhibitor that has completed Phase 3 clinical trials and is currently in the regulatory submission process. The company also maintains a joint venture, GT Diagnostics, which develops digital assessment tools for early detection and monitoring of neurodegenerative conditions.